Skip to main content

Kura Oncology(KURA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Latest News

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
GlobeNewswire - Tue Nov 5, 8:09AM CST
GlobeNewswire
Tue Nov 5, 8:09AM CST
Kura Oncology to Report Third Quarter 2024ย Financial Results
GlobeNewswire - Thu Oct 31, 6:30AM CDT
GlobeNewswire
Thu Oct 31, 6:30AM CDT
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
GlobeNewswire - Thu Oct 24, 6:30AM CDT
GlobeNewswire
Thu Oct 24, 6:30AM CDT
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
GlobeNewswire - Wed Oct 23, 6:30AM CDT
GlobeNewswire
Wed Oct 23, 6:30AM CDT
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
GlobeNewswire - Mon Jun 17, 8:00AM CDT
GlobeNewswire
Mon Jun 17, 8:00AM CDT
2 Incredible Growth Stocks to Buy Hand Over Fist
Motley Fool - Wed May 8, 7:30AM CDT
Motley Fool
Wed May 8, 7:30AM CDT
These two healthcare growth stocks could have a lot more room to run.
For Number Cruncher column in Globe Investor/ROB only.
U.S. equities in the spotlight for price trend enthusiasts
The Globe and Mail - Thu Mar 7, 5:12PM CST
The Globe and Mail
Thu Mar 7, 5:12PM CST
We are looking for price trend-focused opportunities in U.S.-listed equities
Healthcare - iStock-1346675584
Kura Oncology (KURA) Offers Speculators a Profit-Scalping Opportunity
Barchart - Tue Jan 16, 12:00PM CST
Barchart
Tue Jan 16, 12:00PM CST
With bullish traders anticipating a quick pop in KURA stock, outside observers need to pay attention, especially because of the underlying short position.
7 Best Cancer Stocks to Invest in Now
MarketBeat - Fri Jul 28, 2023
MarketBeat
Fri Jul 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Wall Street - NYSE Full View
Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data
Barchart - Wed Jun 14, 2023
Barchart
Wed Jun 14, 2023
June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserveโ€™s interest rate decision while also awaiting crucial U.S. PPI data.
Kura Oncology Reports Second Quarter 2022 Financial Results
Globe Newswire - Wed Aug 3, 2022
Globe Newswire
Wed Aug 3, 2022
โ€“ Recommended Phase 2 dose for ziftomenib identified, pending FDA review โ€“ โ€“ Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Globe Newswire - Tue Aug 2, 2022
Globe Newswire
Tue Aug 2, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology to Participate in Three Upcoming Investor Conferences
Globe Newswire - Thu May 26, 2022
Globe Newswire
Thu May 26, 2022
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports First Quarter 2022 Financial Results
Globe Newswire - Wed May 4, 2022
Globe Newswire
Wed May 4, 2022
โ€“ Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter โ€“ โ€“...
Kura Oncology to Report First Quarter 2022 Financial Results
Globe Newswire - Wed Apr 27, 2022
Globe Newswire
Wed Apr 27, 2022
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
Globe Newswire - Fri Apr 8, 2022
Globe Newswire
Fri Apr 8, 2022
โ€“ Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
Globe Newswire - Tue Mar 8, 2022
Globe Newswire
Tue Mar 8, 2022
โ€“ Presentations to highlight significant opportunities targeting farnesyl transferase inhibition โ€“...
Kura Oncology to Participate in Two Upcoming Investor Conferences
Globe Newswire - Mon Feb 28, 2022
Globe Newswire
Mon Feb 28, 2022
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire - Thu Feb 24, 2022
Globe Newswire
Thu Feb 24, 2022
โ€“ Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML โ€“ โ€“ Multiple milestones and data readouts from KOMET-001 expected...
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire - Thu Feb 17, 2022
Globe Newswire
Thu Feb 17, 2022
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
Globe Newswire - Thu Feb 10, 2022
Globe Newswire
Thu Feb 10, 2022
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Expands Leadership Team with Key Promotions
Globe Newswire - Tue Feb 1, 2022
Globe Newswire
Tue Feb 1, 2022
โ€“ Expanded leadership team to support and advance the Company's rapid growth โ€“...
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 inย Acute Myeloid Leukemia
Globe Newswire - Thu Jan 20, 2022
Globe Newswire
Thu Jan 20, 2022
โ€“ FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome โ€“ โ€“ KOMET-001 study to resume screening and...
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
Globe Newswire - Thu Dec 16, 2021
Globe Newswire
Thu Dec 16, 2021
โ€“ Preclinical data suggest HRAS and PI3Kฮฑ are co-dependent oncogenes in HNSCC โ€“ โ€“ Combination has potential to address up to 50% of patients with HNSCC โ€“ ...